Beijing Konruns Pharmaceutical Co Ltd Asset Resilience Ratio
Beijing Konruns Pharmaceutical Co Ltd asset resilience ratio. Beijing Konruns Pharmaceutical Co Ltd (603590) has an Asset Resilience Ratio of 10.55% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 603590 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Beijing Konruns Pharmaceutical Co Ltd (2019–2025)
Asset resilience ratio of Beijing Konruns Pharmaceutical Co Ltd from 2019 to 2025. This chart shows how Beijing Konruns Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Beijing Konruns Pharmaceutical Co Ltd (603590) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Beijing Konruns Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Beijing Konruns Pharmaceutical Co Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥430.11 Million | 10.55% |
| Total Liquid Assets | CN¥430.11 Million | 10.55% |
Asset Resilience Insights
- Moderate Liquidity: Beijing Konruns Pharmaceutical Co Ltd has 10.55% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Beijing Konruns Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Konruns Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
Beijing Konruns Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2019–2025)
Beijing Konruns Pharmaceutical Co Ltd asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Beijing Konruns Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.22% | CN¥500.43 Million ≈ $73.23 Million |
CN¥4.09 Billion ≈ $599.23 Million |
+0.72pp |
| 2024-12-31 | 11.50% | CN¥450.66 Million ≈ $65.95 Million |
CN¥3.92 Billion ≈ $573.57 Million |
+1.01pp |
| 2023-12-31 | 10.48% | CN¥396.41 Million ≈ $58.01 Million |
CN¥3.78 Billion ≈ $553.25 Million |
+2.30pp |
| 2022-12-31 | 8.19% | CN¥280.37 Million ≈ $41.03 Million |
CN¥3.42 Billion ≈ $501.16 Million |
+7.92pp |
| 2021-12-31 | 0.27% | CN¥9.04 Million ≈ $1.32 Million |
CN¥3.37 Billion ≈ $493.33 Million |
-4.52pp |
| 2020-12-31 | 4.79% | CN¥181.36 Million ≈ $26.54 Million |
CN¥3.79 Billion ≈ $553.96 Million |
+4.73pp |
| 2019-12-31 | 0.06% | CN¥2.00 Million ≈ $293.16K |
CN¥3.17 Billion ≈ $464.43 Million |
-- |
About Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in p… Read more